☆ 4.5 Article

Transformation of Lung Squamous Cell Carcinoma to Small Cell Lung Cancer After Immunotherapy Resistance: A Case Report

CANCER MANAGEMENT AND RESEARCH (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial

Jifang Gong et al.

Summary: This first-in-human phase 1 trial evaluated the safety, pharmacokinetics, preliminary efficacy, and biomarkers of sugemalimab in Chinese patients with advanced malignancies. The results showed that sugemalimab was well-tolerated and demonstrated promising antitumor activity as monotherapy or in combination with chemotherapy.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

Add to Collection

Review Oncology

Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies

Antonio Passaro et al.

Summary: A proportion of lung cancer patients can benefit from immune checkpoint inhibitors (ICIs), but most patients experience disease progression during or after treatment. Immune resistance has different definitions based on clinical and biological features. Combination therapies are being developed to delay or prevent resistance to ICIs.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Review Oncology

First-Line Immunotherapy for Non-Small-Cell Lung Cancer

Martin Reck et al.

Summary: The past decade has seen significant progress in the treatment of metastatic non-small-cell lung cancer, with the development of specific antibodies leading to improved survival for many patients. Currently, nearly all mNSCLC patients receive PD-1 or PD-L1 therapy in the first-line setting, except those with targetable oncogenes.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial

Caicun Zhou et al.

Summary: The GEMSTONE-302 trial showed that sugemalimab plus chemotherapy significantly improved progression-free survival in previously untreated squamous and non-squamous metastatic NSCLC patients compared to placebo plus chemotherapy, regardless of PD-L1 expression. These findings have important implications for the first-line treatment of squamous and non-squamous metastatic NSCLC.

LANCET ONCOLOGY (2022)

Add to Collection

Article Oncology

Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial

Qing Zhou et al.

Summary: The efficacy and safety of sugemalimab, an anti-PD-L1 antibody, were assessed in patients with unresectable stage III non-small-cell lung cancer (NSCLC) who had not progressed after concurrent or sequential chemoradiotherapy. The results showed that sugemalimab significantly prolonged progression-free survival in these patients.

LANCET ONCOLOGY (2022)

Add to Collection

Article Immunology

The Multi-Omics Analysis of Key Genes Regulating EGFR-TKI Resistance, Immune Infiltration, SCLC Transformation in EGFR-Mutant NSCLC

Zhi Wang et al.

Summary: In this study, we identified potential genes associated with EGFR-TKI resistance in lung cancer and found that SPP1 may play a crucial role in resistance to EGFR-TKIs. Furthermore, high expression of SPP1 was also associated with tumor immune infiltration and poor prognosis.

JOURNAL OF INFLAMMATION RESEARCH (2022)

Add to Collection

Article Pharmacology & Pharmacy

Sugemalimab: First Approval

Sohita Dhillon et al.

Summary: Sugemalimab, a fully human monoclonal antibody, has been approved in China for the first-line treatment of EGFR gene mutation and ALK-negative metastatic NSCLC. Clinical studies are also underway to evaluate its efficacy in various other cancer types.

DRUGS (2022)

Add to Collection

Article Oncology

First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer: CS-Lung-003 prospective observational registry study

Kenichiro Kudo et al.

Summary: Repeat rebiopsy may increase the ability to detect T790M mutation positivity rate in patients with T790M-negative non-small-cell lung cancer (NSCLC) detected by the first rebiopsy.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)

Add to Collection

Article Respiratory System

Genomic Analysis Reveals the Prognostic and Immunotherapeutic Response Characteristics of Ferroptosis in Lung Squamous Cell Carcinoma

Yinhe Feng et al.

Summary: This study established a new algorithm based on the ferroptosis score to determine the prognosis and response to immunotherapy of patients with lung squamous cell carcinoma (LUSC). The results showed significant differences in prognosis and immunotherapy response among patients with different ferroptosis scores.

LUNG (2022)

Add to Collection

Article Oncology

Real-World longitudinal practice patterns in the use of PD-1 and PD-L1 inhibitors as First-Line therapy in patients with Non-Small cell lung cancer in the United States

Rajwanth Veluswamy et al.

Summary: This study investigated the changes in first-line therapies for non-small cell lung cancer (NSCLC) in the United States since the introduction of programmed cell death protein-1 (PD-1) and programmed death ligand-1 (PD-L1) immune checkpoint inhibitors. The results showed a significant increase in the use of PD-1 and PD-L1 inhibitors, especially in combination with chemotherapy, for first-line treatment. A considerable proportion of patients still received chemotherapy alone.

CANCER MEDICINE (2022)

Add to Collection

Review Immunology

Whole-Process Treatment of Combined Small Cell Lung Cancer Initially Diagnosed as Lung Squamous Cell Carcinoma: A Case Report and Review of the Literature

Yong Dong et al.

Summary: The rarity and complexity of histology lead to the low diagnosis rate and high misdiagnosis rate of combined small cell lung cancer (C-SCLC). Currently, there is no commonly recommended therapeutic regimen for C-SCLC, and it mainly conforms to SCLC treatment. We report a case of a patient initially diagnosed as stage IIIA lung squamous cell carcinoma who underwent radical resection after neoadjuvant immunochemotherapy, and the final surgical pathology showed C-SCLC containing three different histological components. Our literature review explores the therapeutic effect of neoadjuvant immunotherapy in C-SCLC, explains the therapeutic conflicts among heterogeneous components, and analyzes the pathology complexity at the tissue, cell, and molecule levels in-depth, including possible genetic characteristics, origin, and evolution through next-generation sequencing (NGS).

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Oncology

Clinicopathologic and molecular characteristics of EGFR-mutant lung adenocarcinomas that transform to small-cell lung cancer after TKI therapy

Li Yu et al.

Summary: Small cell transformation is a common mechanism of drug resistance in EGFR-mutated NSCLC, with patients typically presenting with poorly differentiated adenocarcinoma and most having TP53 mutation but not universal RB1 loss. WNK1 mutation may be associated with improved survival as a potential resistance mechanism to TKIs.

TRANSLATIONAL LUNG CANCER RESEARCH (2022)

Add to Collection

Article Oncology

Small cell lung cancer transformation and tumor heterogeneity after sequential targeted therapy and immunotherapy in EGFR-mutant non-small cell lung cancer: A case report

Meng-Hang Yang et al.

Summary: This case suggests that SCLC transformation and tumor heterogeneity should be taken into consideration when disease progression occurs in advanced NSCLC, whether receiving targeted therapy or immunotherapy.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

Jamie E. Chaft et al.

Summary: This study examined the use of neoadjuvant atezolizumab in patients with resectable non-small cell lung cancer. It found that profiles of innate immune cells in pre-treatment peripheral blood may predict pathological response after neoadjuvant atezolizumab, but further studies are needed to confirm these findings.

NATURE MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR-Mutant Lung Adenocarcinoma

Po-Hsin Lee et al.

Summary: This study aimed to investigate the incidence of histological transformation and its impact on treatment outcomes in patients with EGFR-mutant lung adenocarcinoma receiving third-generation EGFR-TKI therapy. The results revealed that a subset of patients experienced histological transformation, which rendered the treatment ineffective and was associated with shorter overall survival. Therefore, repeating biopsy to identify histological transformation should be considered to guide treatment decisions.

MEDICINA-LITHUANIA (2022)

Add to Collection

Article Oncology

Real-world data prognostic model of overall survival in patients with advanced NSCLC receiving anti-PD-1/PD-L1 immune checkpoint inhibitors as second-line monotherapy

Cristina Julian et al.

Summary: This retrospective cohort study aimed to investigate prognostic factors of overall survival in patients with advanced non-small cell lung cancer and develop a novel prognostic model. Factors such as low albumin and chloride levels, Eastern Cooperative Oncology Group performance status score, and high alkaline phosphatase and white blood cell levels were identified as risk-increasing prognostic factors. The model's performance was validated using data from the OAK trial, showing a c-index of 0.65 for the OAK trial validation cohort and 0.67 for the real-world data cohort.

CANCER REPORTS (2022)

Add to Collection

Article Oncology

Small cell transformation of non-small cell lung cancer under immunotherapy: Case series and literature review

Takuma Imakita et al.

Summary: Small cell transformation is recognized as an important resistance mechanism in cancer immunotherapy, with several similar cases reported. When non-small cell lung cancer progresses after immunotherapy, rebiopsy for small cell transformation should be encouraged for clarification of resistance mechanisms.

THORACIC CANCER (2021)

Add to Collection

Article Oncology

Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study

Wenxian Wang et al.

Summary: The study found that TP53 and RB1 mutations were common in patients with SCLC transformation in China, regardless of whether first/second-generation or third-generation EGFR-TKIs were used. After transformation to SCLC, platinum-etoposide was the most common treatment regimen, and anlotinib showed good efficacy in these patients.

LUNG CANCER (2021)

Add to Collection

Article Oncology

Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer

David Waterhouse et al.

Summary: Real-world outcomes for patients with advanced NSCLC treated with 1L I-O therapy in the United States showed longer median OS in patients with high PD-L1 expression compared to low expression, but survival estimates were generally lower than those reported in pivotal clinical trials.

LUNG CANCER (2021)

Add to Collection

Article Oncology

Case Report: Transformation From Non-Small Cell Lung Cancer to Small Cell Lung Cancer During Anti-PD-1 Therapy: A Report of Two Cases

Qian Shen et al.

Summary: Histological transformation of lung squamous cell carcinomas to small cell lung cancer (SCLC) during anti-PD-1 therapy is uncommon but is a potential mechanism of resistance to immunotherapy. Disease progression should prompt re-biopsy to diagnose potential histological changes and assess the need for a change in treatment.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

Factors related to rapid progression of non-small cell lung cancer in Chinese patients treated using single-agent immune checkpoint inhibitor treatment

Liang Zhang et al.

THORACIC CANCER (2020)

Add to Collection

Article Oncology

Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?

Kartik Sehgal et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection

Review Oncology

The Resistance Mechanisms of Lung Cancer Immunotherapy

Fen Wang et al.

FRONTIERS IN ONCOLOGY (2020)

Add to Collection

Article Oncology

Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer

Jair Bar et al.

LUNG CANCER (2019)

Add to Collection

© Peeref 2019-2024. All rights reserved.